Physician profile
Sami Bahna
NPI 1902823966
$11,275.73
in general payments reported to CMS, 2019-2025
20 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,439 · 2020: $249 · 2022: $125 · 2023: $1,165 · 2024: $778 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,462.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $4,608.94 | 2019-2025 | Joenja, Ruconest |
| Biocryst Pharmaceuticals, INC. | $3,063.40 | 2019 | |
| Biocryst US Sales Co., LLC | $649.61 | 2022-2025 | Orladeyo |
| Genzyme Corporation | $526.13 | 2023-2025 | |
| Csl Behring | $484.70 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Blueprint Medicines Corporation | $270.27 | 2023 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $242.93 | 2020-2023 | Tezspire |
| Grifols Shared Services North America, INC. | $151.78 | 2024 | Xembify |
| Glaxosmithkline, LLC. | $149.29 | 2019-2023 | |
| X4 Pharmaceuticals, INC. | $135.00 | 2024 | Xolremdi |
| Genentech, INC. | $125.00 | 2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $124.47 | 2020 | |
| Ionis Pharmaceuticals, INC. | $121.98 | 2025 | Dawnzera |
| Sanofi US Services INC. | $119.81 | 2025 | |
| Aquestive Therapeutics, INC. | $119.22 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $117.93 | 2023 | Tezspire |
| Optinose US, INC. | $110.94 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.00 | 2025 | Takhzyro |
| Dermavant Sciences, INC. | $33.79 | 2023 | Vtama |
| Genentech USA, INC. | $21.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Bahna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.